Compare QTRX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QTRX | ANL |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 293.4M |
| IPO Year | 2017 | 2022 |
| Metric | QTRX | ANL |
|---|---|---|
| Price | $3.92 | $7.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $11.33 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 683.1K | 185.4K |
| Earning Date | 03-02-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,632,000.00 | N/A |
| Revenue This Year | $25.49 | N/A |
| Revenue Next Year | $9.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 64.52 | N/A |
| 52 Week Low | $3.64 | $0.88 |
| 52 Week High | $8.77 | $12.09 |
| Indicator | QTRX | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 24.33 | 40.32 |
| Support Level | N/A | $1.36 |
| Resistance Level | $6.27 | $9.98 |
| Average True Range (ATR) | 0.29 | 0.77 |
| MACD | -0.09 | -0.27 |
| Stochastic Oscillator | 18.55 | 16.36 |
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.